<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="133202">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01367743</url>
  </required_header>
  <id_info>
    <org_study_id>2009-017081-23</org_study_id>
    <nct_id>NCT01367743</nct_id>
  </id_info>
  <brief_title>Study Comparing the Efficacy and Tolerability of Epinephrine and Norepinephrine in Cardiogenic Shock</brief_title>
  <acronym>OptimaCC</acronym>
  <official_title>Optimizing the Use of Vasopressor After Coronary Reperfusion in Cardiogenic Shock Secondary to Myocardial Infarction. Pathophysiological Study Comparing the Efficacy and Cardio-circulatory Tolerability of Epinephrine and Norepinephrine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy and tolerability of norepinephrine and epinephrine in cardiogenic shock after
      reperfused myocardial infarction will be compared, by following cardiac index evolution as
      main criteria. The study is a pilot pathophysiological study, randomized, double blind and
      multicenter.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Cardiogenic shock secondary to myocardial infarction is a frequent pathology in reanimation
      and is associated with high mortality (50%). Hemodynamic management and notably the choice
      of vasopressor in cardiogenic shock states secondary to myocardial infarction (cardiac index
      &lt; 2.2 l/min/m-2) is not codified. There are two opposite views: a) the first is based on the
      fact that an hypotensive patient with low cardiac output is primarily in need of an
      inotropic agent and that, consequently, epinephrine is the molecule of choice (inotropic and
      vasoconstrictor); b) the second is based on the fact that hypotension also reflects a
      certain degree of vascular failure and vascular vasoplegia and therefore norepinephrine is
      the molecule of choice along with, if needed, the eventual addition of dobutamine in order
      to separately titrate vasoconstriction and inotropism.

      Study hypotheses: epinephrine could facilitate myocardial function by providing the latter
      with its preferred substrate (lactate) and thus induce a higher cardiac index along with
      increased energy expenditure. Norepinephrine is the therapy of choice of hypotensive states;
      nevertheless its lack of inotropic effect could theoretically exacerbate myocardial failure.
      Thus, the aim of the study is to compared the efficiency and the tolerability of
      norepinephrine and epinephrine in cardiogenic shock after reperfused myocardial infarction.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compared effects of investigated drugs on cardiac index</measure>
    <time_frame>participants will be followed until release from ICU, an expected average of 2 weeks</time_frame>
    <description>effectiveness of the treatment assessed by the evolution of cardiac index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compared effects of investigated drugs on heart rate and cardiac power index</measure>
    <time_frame>participants will be followed until release from ICU, an expected average of 2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pro/anti-inflammatory cytokines</measure>
    <time_frame>participants will be followed until release from ICU, an expected average of 2 weeks</time_frame>
    <description>establish the pro/anti-inflammatory profile of cardiogenic shock in terms of cytokines and its evolution</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>epinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>norepinephrine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epinephrine/norepinephrine</intervention_name>
    <description>perfusion of commercial epinephrine or norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg</description>
    <arm_group_label>epinephrine</arm_group_label>
    <arm_group_label>norepinephrine</arm_group_label>
    <other_name>vasopressor</other_name>
    <other_name>catecholamine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  man or woman older than 18 years

          -  cardiogenic shock due to myocardial infarction treated by angioplasty

          -  SAP &lt; 90 MM Hg or MAP &lt; 65 mm Hg without vasopressor

          -  sign of tissue hypoperfusion

          -  cardiac index &lt; 2.2 l/mn/m2 in the absence of vasopressive or inotropic therapy

          -  pulmonary artery occlusion pressure &gt; 15 mm Hg or echocardiographic evidence of high
             pressure (mitral profile)

          -  exclusion of covert hypovolemia : Delta PP if feasible should be &gt; 13% (patient
             adapted to the ventilator and sinus rhythm) and /or no response to passive leg
             raising

          -  ejection fraction &lt; 40% in ultrasound without inotrope support. This criteria will
             not be taken into account in instances of treatment with dopamine, norepinephrine,
             epinephrine, dobutamine or milrinone.

        Exclusion Criteria:

          -  shock of other origin

          -  immediate indications for mechanical assistance device

          -  minor aged patients

          -  patients for whom written consent - by patient or family - has not been obtained.
             Given the seriousness of the medical situation at the time of inclusion, patient
             consent will be difficult if not impossible to obtain. The inclusion will only be
             possible after information is provided and consent is obtained from a family member.
             As soon as possible, protocol information will be issued to the patient in order to
             obtain consent for continuance.

          -  cardiac arrest with early signs of cerebral anoxia.

          -  septic, toxic and obstructive cardiomyopathy

          -  arrhythmogenic cardiomyopathy

          -  patient with coronary insufficiency

          -  patient with ventricular rhythm disorders

          -  patient treated with a medicine listed in contre indication

          -  patient without social assurance

          -  patient major under legal protection or safeguard justice
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philippe VIGNON, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LEVY Bruno, Doctor</last_name>
    <phone>+33 3 83 15 44 69</phone>
    <email>b.levy@chu-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>GIBOT Sebastien, Doctor</last_name>
    <phone>+33 3 83 85 42 70</phone>
    <email>s.gibot@chu-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Nancy Brabois university hospital</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <state>Meurthe et Moselle</state>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Levy Bruno, PhD</last_name>
      <phone>+33 3 83 15 44 69</phone>
      <email>b.levy@chu-nancy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Gibot Sebastien, PhD</last_name>
      <phone>+33 3 83 15 29 70</phone>
      <email>s.gibot@chu-nancy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>LEVY Bruno, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de BESANCON / HÃ´pital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>CAPELLIER Gilles, Pr</last_name>
    </contact>
    <investigator>
      <last_name>CAPELLIER Gilles, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de DIJON</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>QUENOT Jean Pierre, Dr</last_name>
    </contact>
    <investigator>
      <last_name>QUENOT Jean Pierre, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de LIMOGES HÃ´pital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vignon Philippe, Pr</last_name>
    </contact>
    <investigator>
      <last_name>VIGNON Philippe, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM HÃ´pital NORD</name>
      <address>
        <city>Marseille</city>
        <zip>13015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEONE Marc, Pr</last_name>
    </contact>
    <investigator>
      <last_name>LEONE Marc, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chr Metz Thionville</name>
      <address>
        <city>Metz</city>
        <zip>57000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LOUIS Guillaume, Dr</last_name>
    </contact>
    <investigator>
      <last_name>LOUIS Guillaume, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de MULHOUSE</name>
      <address>
        <city>Mulhouse</city>
        <zip>68070</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>GUIOT Philippe, Dr</last_name>
    </contact>
    <investigator>
      <last_name>GUIOT Philippe, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP-HÃ´pital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cariou Alain, Dr</last_name>
    </contact>
    <investigator>
      <last_name>CARIOU Alain, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de STRASBOURG / NHC</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MEZIANI Ferhat, Pr</last_name>
    </contact>
    <investigator>
      <last_name>MEZIANI Ferhat, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chru Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LEGRAS Annick, Dr</last_name>
    </contact>
    <investigator>
      <last_name>LEGRAS Annick, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 5, 2016</lastchanged_date>
  <firstreceived_date>May 10, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myocardial infarction</keyword>
  <keyword>epinephrine</keyword>
  <keyword>norepinephrine</keyword>
  <keyword>cardiac output</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Shock</mesh_term>
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Norepinephrine</mesh_term>
    <mesh_term>Epinephrine</mesh_term>
    <mesh_term>Racepinephrine</mesh_term>
    <mesh_term>Epinephryl borate</mesh_term>
    <mesh_term>Vasoconstrictor Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
